Featured Pharma Online Editorial

  1. Big Data And AI In Pharma Development And Manufacturing: An Inside Look 2/27/2019

    Artificial intelligence and Big Data have the potential to lower the cost and time of drug trials, to better determine patient outcomes with established drugs, and to better design new drugs.

  2. Environmental Risks & The Life Science Supply Chain: Lessons Learned From Hurricane Maria 1/15/2018

    Looking back at the hurricane season from the perspective of supply chain risk — and specifically risks that have impacted the life sciences supply chain — there are many lessons to be learned.

  3. 5 Proven Steps To Successfully Select & Onboard Outsourced Logistics Partners 1/23/2017

    In preceding articles in this series, we reviewed some of the challenges and remediation approaches for the storage and distribution of life science products, highlighting some of the specific risks related to storage, transportation, and material control across an extended chain of custody. This brings us to the final article, in which we will discuss best practices for selecting the partners that will be an extension of your staff for monitoring and control across an ever-changing global landscape.

  4. 2nd Draft Guidance Under DSCSA Offers Clarity For 3PLs As January Deadline Approaches 10/28/2014

    Earlier this month, the FDA announced the availability of the second draft guidance under the Drug Supply Chain Security Act (DSCSA), titled The Effect of Section 585 of the FD&C Act on Drug Product Tracing and Wholesale Drug Distributor and Third-Party Logistics Provider Licensing Standards and Requirements: Questions and Answers. While clarifying information is provided, the guidance is still in draft form and more information from industry will need to be collected in order to drive it to a finalized state.   

  5. The Difference Between Logistics Management And Logistics Control In Life Sciences 5/11/2013

    Life science products have a distinct logistical profile; the nuances between a fine chemical and a medical compound or medical devices and computer hardware have significant regulatory differences. When determining the logistics plan for a product it is critical to remember that it is not just a box. By Paddy Hanlon, Senior Director, Business Development, Marken